Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Key updates in MPNs from ASH 2018

Claire Harrison • 7 Jan 2019
ASH 2018
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Systemic Mastocytosis Avapritinib Hydroxyurea Interferon Pegaptanib PRM-151 Ruxolitinib
MAJIC

Claire Harrison, MD, FRCP, FRCPath, of the Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives her perspective on the latest data in myeloproliferative neoplasms (MPNs) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Key highlights include driver mutations, prognostics, and longer-term data from the MAJIC study (ISRCTN61925716).

More from Claire Harrison

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
1:58
The value of novel JAK2 and CALR-targeted therapies in MPNs
Claire Harrison • 24 Apr 2023
1:39
The role of transplantation in MPNs & factors to consider when selecting patients for transplant
Claire Harrison • 24 Apr 2023
2:33
Optimizing current treatment approaches in myelofibrosis
Claire Harrison • 24 Apr 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals